Related Experiment Video
Updated: Apr 16, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
24.9K
[Treatment of hepatitis C]
M D Schneider1, B Kronenberger, S Zeuzem
1Zentrum der Inneren Medizin, Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland, maximilian-david.schneider@kgu.de.
Der Internist
|March 13, 2015
Summary
New antiviral drugs offer a cure for chronic hepatitis C virus (HCV) infection, achieving over 90% sustained virologic response. These interferon-free treatments are effective for most patients within 12-24 weeks.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Context:
- Chronic hepatitis C virus (HCV) infection remains a significant global health concern, leading to liver cirrhosis and hepatocellular carcinoma.
- Recent advancements in antiviral therapies have transformed HCV management, offering improved efficacy and safety profiles.
Purpose:
- To summarize the current landscape of directly acting antiviral (DAA) drug therapies for chronic hepatitis C virus infection.
- To outline modern treatment strategies, including recommended durations and specific drug combinations for various HCV genotypes.
Summary:
- Directly acting antiviral (DAA) drugs have led to sustained virologic response rates exceeding 90% in patients with chronic HCV infection.
- Current interferon-free DAA regimens are administered for 12-24 weeks, with shorter courses available for select individuals.
- Specific DAA combinations, including sofosbuvir, simeprevir, daclatasvir, ledipasvir, paritaprevir, ombitasvir, and dasabuvir, are effective for HCV genotype 1 treatment.
Impact:
- DAA therapies represent a major breakthrough in treating HCV, significantly reducing the burden of liver disease and transplantation needs.
- The high efficacy and improved tolerability of modern DAA regimens facilitate widespread treatment and potential HCV eradication.
More Related Videos
Related Concept Videos
01:25Hepatitis
63
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
01:10Retrovirus Life Cycles
50.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
01:30Inhibitors of Viral Protein Synthesis
37
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
37
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
358
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
358
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
2.4K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.4K
01:24Cystic Fibrosis: Management
647
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
647